Harrow- 8.625% NT REDEEM 30/04/2026 USD 25 Profit Margin

The latest profit margin for HROWL is -5.57% as of March 2026. That compares with -10.19% in the prior-year period — up 45.4% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Harrow- 8.625% NT REDEEM 30/04/2026 USD 25's historical trend and sector peers before judging valuation or financial health.

Over the past year, HROWL's profit margin moved from -10.19% to -5.57% — a 45.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Harrow- 8.625% NT REDEEM 30/04/2026 USD 25's valuation or profitability profile.

Against Healthcare companies, HROWL currently prints -5.57% for profit margin, while the sector average sits near 14.34%. That is roughly 138.8% below the sector mean. Large gaps often invite a closer look at Harrow- 8.625% NT REDEEM 30/04/2026 USD 25's growth, margins, and balance sheet.

Profit Margin shows how effectively Harrow- 8.625% NT REDEEM 30/04/2026 USD 25 converts resources into returns. At -5.57%, HROWL may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -10.19% in the prior-year period — up 45.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting HROWL's profit margin (-5.57%), review year-over-year change from -10.19%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.